Alex H Gifford
Overview
Explore the profile of Alex H Gifford including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
754
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zuckerman J, Hinton A, Lahiri T, Teneback C, Jia S, Mermis J, et al.
Pediatr Pulmonol
. 2025 Jan;
60(1):e27487.
PMID: 39835779
Objective: Although studies have examined changes in C-reactive protein (CRP) during pulmonary exacerbations (PEX) in people with cystic fibrosis (PwCF), few have evaluated CRP profiles across age groups. Here, we...
2.
Everhart R, McWilliams E, Maggs J, Sawicki G, Sconiers T, Smith K, et al.
J Cyst Fibros
. 2024 Nov;
24(1):187-192.
PMID: 39578180
Background: Elexacaftor/tezacaftor/ivacaftor (ETI) has profoundly affected the health and lives of many people with CF (pwCF). The rapid change in health for pwCF taking ETI provided them an opportunity to...
3.
Maggs J, Sawicki G, Bacon C, McWilliams E, Yablon D, Ertman B, et al.
Contemp Clin Trials
. 2024 Nov;
148:107752.
PMID: 39557157
Background: As people with cystic fibrosis (PWCF) live longer due to the breakthrough drug elexacaftor-tezacaftor-ivacaftor (ETI), they have questioned whether other CF therapies could be safely discontinued. SIMPLIFY was the...
4.
Bruening Wajda K, Gifford A
J Cyst Fibros
. 2024 Oct;
23(6):1038-1039.
PMID: 39370311
No abstract available.
5.
Gifford A, Odem-Davis K, Kloster M, OSullivan B, Omlor G, Millard S, et al.
J Cyst Fibros
. 2024 Sep;
24(1):91-97.
PMID: 39278759
Background: Highly effective CFTR modulator therapy (HEMT) has improved the health of many people with cystic fibrosis (pwCF), offering opportunities to discontinue burdensome therapies. SIMPLIFY included randomized, controlled trials that...
6.
Mayer-Hamblett N, Gifford A, Kloster M, Russell R, Braun A, Gibson R, et al.
Ann Am Thorac Soc
. 2024 Jul;
21(11):1507-1515.
PMID: 39041864
Evaluating approaches to reduce treatment burden is a research priority among people with cystic fibrosis on highly effective modulators, including elexacaftor-tezacaftor-ivacaftor (ETI). We sought to evaluate the impact of discontinuing...
7.
Jia S, Wang Y, Ross M, Zuckerman J, Murray S, Han M, et al.
J Cyst Fibros
. 2024 Mar;
23(5):878-884.
PMID: 38490920
Background: Iron deficiency (ID) is a common extrapulmonary manifestation in cystic fibrosis (CF). CF transmembrane conductance regulator (CFTR) modulator therapies, particularly highly-effective modulator therapy (HEMT), have drastically improved health status...
8.
Donaldson S, Corcoran T, Pilewski J, Laube B, Mogayzel P, Ceppe A, et al.
J Cyst Fibros
. 2024 Feb;
23(3):457-460.
PMID: 38355350
Many people with CF (pwCF) desire a reduction in inhaled treatment burden after initiation of elexacaftor/tezacaftor/ivacaftor. The randomized, open-label SIMPLIFY study showed that discontinuing hypertonic saline (HS) or dornase alfa...
9.
Gold L, Hansen R, Mayer-Hamblett N, Nichols D, Gifford A, Kloster M, et al.
J Manag Care Spec Pharm
. 2023 Dec;
30(1):26-33.
PMID: 38153868
Background: Dornase alfa and hypertonic saline are mucoactive therapies that can improve respiratory symptoms in people with cystic fibrosis (CF). A recent randomized control trial showed that participants with well-preserved...
10.
Wajda K, Roesch E, Gifford A
Curr Opin Pulm Med
. 2023 Aug;
29(6):580-586.
PMID: 37611027
Purpose Of Review: Cystic fibrosis is a genetic disease that increases risk of death from respiratory failure because of impairment in mucociliary clearance. Complex daily care regimens including medications and...